Trial Outcomes & Findings for Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12 (NCT NCT06854601)
NCT ID: NCT06854601
Last Updated: 2025-08-17
Results Overview
The Swanson, Nolan and Pelham Teacher and Parent Rating Scale (SNAP-IV) is a 90-question self-report inventory designed to measure attention deficit hyperactivity disorder and oppositional defiant disorder symptoms in children and young adults. The SNAP-IV is based on a 0 to 3 rating scale: Not at all = 0, Just a little = 1, Often = 2, and Very often = 3. The questions measure different domains of ADHD and ODD. Subscale scores are calculated by summing the scores on the subset and dividing by the number of items in the subset. The main criterion for the treatment efficacy was the mean change in the total score on the "inattention" and "hyperactivity/impulsivity" subscales after 6 weeks of therapy. A conclusion of superiority of Mexidol over placebo can be made if the upper limit of the 95% confidence interval for the difference in mean changes is negative. 55 point scale: min value 0, max value 54, higher scores mean a worse outcome.
COMPLETED
PHASE3
333 participants
Visit 5 (after 6 weeks of therapy) compared to the baseline level (Visit 2 Day 1 = Randomization Visit)
2025-08-17
Participant Flow
Participants were recruited based on protocol requirements at 14 clinical sites between July 2019 and May 2020. The first participant was enrolled on 13 July, 2019 and the last participant was enrolled on 22 May, 2020.
Of 340 screened participants, 333 met inclusion criteria and were randomized to treatment.
Participant milestones
| Measure |
Main (Mexidol) + Control (Placebo)
Participants received Mexidol 125 mg 1 tablet orally once a day and Mexidol Placebo matching Mexidol 125 mg 1 tablet orally once a day for 42 days.
|
Main (Mexidol)
Participants received Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
Control (Placebo)
Participants received Mexidol Placebo matching Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
|---|---|---|---|
|
Overall Study
STARTED
|
111
|
111
|
111
|
|
Overall Study
COMPLETED
|
111
|
111
|
110
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
1
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
Main (Mexidol) + Control (Placebo)
n=111 Participants
Participants received Mexidol 125 mg 1 tablet orally once a day and Mexidol Placebo matching Mexidol 125 mg 1 tablet orally once a day for 42 days.
|
Main (Mexidol)
n=111 Participants
Participants received Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
Control (Placebo)
n=111 Participants
Participants received Mexidol Placebo matching Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
Total
n=333 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
111 Participants
n=111 Participants
|
111 Participants
n=111 Participants
|
111 Participants
n=111 Participants
|
333 Participants
n=333 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
0 Participants
n=111 Participants
|
0 Participants
n=111 Participants
|
0 Participants
n=111 Participants
|
0 Participants
n=333 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=111 Participants
|
0 Participants
n=111 Participants
|
0 Participants
n=111 Participants
|
0 Participants
n=333 Participants
|
|
Age, Continuous
|
8 Years
n=111 Participants
|
9 Years
n=111 Participants
|
8 Years
n=111 Participants
|
8 Years
n=333 Participants
|
|
Sex: Female, Male
Female
|
37 Participants
n=111 Participants
|
29 Participants
n=111 Participants
|
31 Participants
n=111 Participants
|
97 Participants
n=333 Participants
|
|
Sex: Female, Male
Male
|
74 Participants
n=111 Participants
|
82 Participants
n=111 Participants
|
80 Participants
n=111 Participants
|
236 Participants
n=333 Participants
|
|
Race and Ethnicity Not Collected
|
—
|
—
|
—
|
0 Participants
Race and Ethnicity were not collected from any participant.
|
|
Region of Enrollment
Russia
|
111 Participants
n=111 Participants
|
111 Participants
n=111 Participants
|
111 Participants
n=111 Participants
|
333 Participants
n=333 Participants
|
|
SNAP-IV, Subscales "Inattention" and "Hyperactivity/Impulsivity" at Visit 2 (Randomization Visit)
|
32.72 score on a scale
STANDARD_DEVIATION 6.73 • n=111 Participants
|
32.37 score on a scale
STANDARD_DEVIATION 6.91 • n=111 Participants
|
33.03 score on a scale
STANDARD_DEVIATION 7.18 • n=111 Participants
|
32.70 score on a scale
STANDARD_DEVIATION 6.93 • n=333 Participants
|
|
SNAP-IV, Subscale "Inattention" at Visit 1 (Screening)
|
17.84 score on a scale
STANDARD_DEVIATION 3.52 • n=111 Participants
|
17.38 score on a scale
STANDARD_DEVIATION 3.79 • n=111 Participants
|
18.00 score on a scale
STANDARD_DEVIATION 3.76 • n=111 Participants
|
17.74 score on a scale
STANDARD_DEVIATION 3.69 • n=333 Participants
|
|
SNAP-IV, Subscale "Hyperactivity/Impulsivity at Visit 1 (Screening)
|
14.88 score on a scale
STANDARD_DEVIATION 4.27 • n=111 Participants
|
14.99 score on a scale
STANDARD_DEVIATION 4.22 • n=111 Participants
|
15.03 score on a scale
STANDARD_DEVIATION 4.51 • n=111 Participants
|
14.96 score on a scale
STANDARD_DEVIATION 4.32 • n=333 Participants
|
|
SNAP-IV, Subscale "Oppositional Defiant Disorder" at Visit 1 (Screening)
|
5.16 score on a scale
STANDARD_DEVIATION 5.42 • n=111 Participants
|
4.64 score on a scale
STANDARD_DEVIATION 5.62 • n=111 Participants
|
5.24 score on a scale
STANDARD_DEVIATION 4.97 • n=111 Participants
|
5 score on a scale
STANDARD_DEVIATION 5.33 • n=333 Participants
|
|
SNAP-IV, Subscale "Connors Index" at Visit 1 (Screening)
|
12.03 score on a scale
STANDARD_DEVIATION 5.11 • n=111 Participants
|
11.39 score on a scale
STANDARD_DEVIATION 5.36 • n=111 Participants
|
12.33 score on a scale
STANDARD_DEVIATION 5.43 • n=111 Participants
|
11.92 score on a scale
STANDARD_DEVIATION 5.30 • n=333 Participants
|
|
SCAS-Parent at Visit 2 (Randomization Visit)
|
13.13 score on a scale
STANDARD_DEVIATION 14.84 • n=111 Participants
|
13.27 score on a scale
STANDARD_DEVIATION 15.36 • n=111 Participants
|
13.27 score on a scale
STANDARD_DEVIATION 13.63 • n=111 Participants
|
13.22 score on a scale
STANDARD_DEVIATION 14.58 • n=333 Participants
|
|
ADHD-RS-IV at Visit 2 (Randomization Visit)
|
32.55 score on a scale
STANDARD_DEVIATION 6.92 • n=111 Participants
|
32.68 score on a scale
STANDARD_DEVIATION 6.90 • n=111 Participants
|
32.77 score on a scale
STANDARD_DEVIATION 6.88 • n=111 Participants
|
32.66 score on a scale
STANDARD_DEVIATION 6.88 • n=333 Participants
|
|
CGI-ADHD-S Scale before treatment
Level 2 (borderline mentally ill)
|
0 Participants
n=111 Participants
|
0 Participants
n=111 Participants
|
0 Participants
n=111 Participants
|
0 Participants
n=333 Participants
|
|
CGI-ADHD-S Scale before treatment
Level 3 (mildly ill)
|
0 Participants
n=111 Participants
|
0 Participants
n=111 Participants
|
0 Participants
n=111 Participants
|
0 Participants
n=333 Participants
|
|
CGI-ADHD-S Scale before treatment
Level 4 (moderately ill)
|
111 Participants
n=111 Participants
|
111 Participants
n=111 Participants
|
111 Participants
n=111 Participants
|
333 Participants
n=333 Participants
|
|
CGI-ADHD-S Scale before treatment
Level 5 (markedly ill)
|
0 Participants
n=111 Participants
|
0 Participants
n=111 Participants
|
0 Participants
n=111 Participants
|
0 Participants
n=333 Participants
|
|
PedMIDAS at Visit 2 (Randomization Visit)
Number of days with limited daily activities
|
10.96 days
STANDARD_DEVIATION 19.76 • n=8 Participants • The scoreson this questionnaire were evaluated only for patientswho were found to have a headache. Thus, the data forcomparing the results at the end of the therapy with theresults at the beginning of the therapy were availablefor 18 patients.
|
0.56 days
STANDARD_DEVIATION 0.51 • n=3 Participants • The scoreson this questionnaire were evaluated only for patientswho were found to have a headache. Thus, the data forcomparing the results at the end of the therapy with theresults at the beginning of the therapy were availablefor 18 patients.
|
1.62 days
STANDARD_DEVIATION 1.82 • n=7 Participants • The scoreson this questionnaire were evaluated only for patientswho were found to have a headache. Thus, the data forcomparing the results at the end of the therapy with theresults at the beginning of the therapy were availablefor 18 patients.
|
5.59 days
STANDARD_DEVIATION 13.66 • n=18 Participants • The scoreson this questionnaire were evaluated only for patientswho were found to have a headache. Thus, the data forcomparing the results at the end of the therapy with theresults at the beginning of the therapy were availablefor 18 patients.
|
|
PedMIDAS at Visit 2 (Randomization Visit)
Number of days with a headache
|
9.04 days
STANDARD_DEVIATION 10.52 • n=8 Participants • The scoreson this questionnaire were evaluated only for patientswho were found to have a headache. Thus, the data forcomparing the results at the end of the therapy with theresults at the beginning of the therapy were availablefor 18 patients.
|
3.22 days
STANDARD_DEVIATION 2.27 • n=3 Participants • The scoreson this questionnaire were evaluated only for patientswho were found to have a headache. Thus, the data forcomparing the results at the end of the therapy with theresults at the beginning of the therapy were availablefor 18 patients.
|
4.86 days
STANDARD_DEVIATION 2.30 • n=7 Participants • The scoreson this questionnaire were evaluated only for patientswho were found to have a headache. Thus, the data forcomparing the results at the end of the therapy with theresults at the beginning of the therapy were availablefor 18 patients.
|
6.44 days
STANDARD_DEVIATION 7.35 • n=18 Participants • The scoreson this questionnaire were evaluated only for patientswho were found to have a headache. Thus, the data forcomparing the results at the end of the therapy with theresults at the beginning of the therapy were availablefor 18 patients.
|
|
PedMIDAS at Visit 2 (Randomization Visit)
Moderate headache severity
|
4.25 scores on ascale
STANDARD_DEVIATION 2.19 • n=8 Participants • The scoreson this questionnaire were evaluated only for patientswho were found to have a headache. Thus, the data forcomparing the results at the end of the therapy with theresults at the beginning of the therapy were availablefor 18 patients.
|
3.00 scores on ascale
STANDARD_DEVIATION 1.00 • n=3 Participants • The scoreson this questionnaire were evaluated only for patientswho were found to have a headache. Thus, the data forcomparing the results at the end of the therapy with theresults at the beginning of the therapy were availablefor 18 patients.
|
3.86 scores on ascale
STANDARD_DEVIATION 1.68 • n=7 Participants • The scoreson this questionnaire were evaluated only for patientswho were found to have a headache. Thus, the data forcomparing the results at the end of the therapy with theresults at the beginning of the therapy were availablefor 18 patients.
|
3.89 scores on ascale
STANDARD_DEVIATION 1.81 • n=18 Participants • The scoreson this questionnaire were evaluated only for patientswho were found to have a headache. Thus, the data forcomparing the results at the end of the therapy with theresults at the beginning of the therapy were availablefor 18 patients.
|
|
PedMIDAS at Visit 2 (Randomization Visit)
Maximal headache severity
|
5.75 scores on ascale
STANDARD_DEVIATION 2.19 • n=8 Participants • The scoreson this questionnaire were evaluated only for patientswho were found to have a headache. Thus, the data forcomparing the results at the end of the therapy with theresults at the beginning of the therapy were availablefor 18 patients.
|
4.00 scores on ascale
STANDARD_DEVIATION 0.00 • n=3 Participants • The scoreson this questionnaire were evaluated only for patientswho were found to have a headache. Thus, the data forcomparing the results at the end of the therapy with theresults at the beginning of the therapy were availablefor 18 patients.
|
6.14 scores on ascale
STANDARD_DEVIATION 2.12 • n=7 Participants • The scoreson this questionnaire were evaluated only for patientswho were found to have a headache. Thus, the data forcomparing the results at the end of the therapy with theresults at the beginning of the therapy were availablefor 18 patients.
|
5.61 scores on ascale
STANDARD_DEVIATION 2.03 • n=18 Participants • The scoreson this questionnaire were evaluated only for patientswho were found to have a headache. Thus, the data forcomparing the results at the end of the therapy with theresults at the beginning of the therapy were availablefor 18 patients.
|
PRIMARY outcome
Timeframe: Visit 5 (after 6 weeks of therapy) compared to the baseline level (Visit 2 Day 1 = Randomization Visit)The Swanson, Nolan and Pelham Teacher and Parent Rating Scale (SNAP-IV) is a 90-question self-report inventory designed to measure attention deficit hyperactivity disorder and oppositional defiant disorder symptoms in children and young adults. The SNAP-IV is based on a 0 to 3 rating scale: Not at all = 0, Just a little = 1, Often = 2, and Very often = 3. The questions measure different domains of ADHD and ODD. Subscale scores are calculated by summing the scores on the subset and dividing by the number of items in the subset. The main criterion for the treatment efficacy was the mean change in the total score on the "inattention" and "hyperactivity/impulsivity" subscales after 6 weeks of therapy. A conclusion of superiority of Mexidol over placebo can be made if the upper limit of the 95% confidence interval for the difference in mean changes is negative. 55 point scale: min value 0, max value 54, higher scores mean a worse outcome.
Outcome measures
| Measure |
Main (Mexidol) + Control (Placebo)
n=111 Participants
Participants received Mexidol 125 mg 1 tablet orally once a day and Mexidol Placebo matching Mexidol 125 mg 1 tablet orally once a day for 42 days.
|
Main (Mexidol)
n=111 Participants
Participants received Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
Control (Placebo)
n=111 Participants
Participants received Mexidol Placebo matching Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
|---|---|---|---|
|
The Average Change in the Total Score Across the "Inattention" and "Hyperactivity/Impulsivity" Subscales of the Swanson, Nolan and Pelham Teacher and Parent Rating Scale (SNAP-IV) After 6 Weeks of Therapy Compared to the Baseline Level.
SNAP-IV at Visit 5
|
25.41 score on a scale
Interval 23.91 to 26.92
|
23.04 score on a scale
Interval 21.49 to 24.58
|
29.10 score on a scale
Interval 27.66 to 30.54
|
|
The Average Change in the Total Score Across the "Inattention" and "Hyperactivity/Impulsivity" Subscales of the Swanson, Nolan and Pelham Teacher and Parent Rating Scale (SNAP-IV) After 6 Weeks of Therapy Compared to the Baseline Level.
Difference at Visit 5 compared to Visit 2
|
-7.31 score on a scale
Interval -8.44 to -6.17
|
-9.33 score on a scale
Interval -10.59 to -8.07
|
-3.93 score on a scale
Interval -5.11 to -2.75
|
SECONDARY outcome
Timeframe: Visit 5 (after 6 weeks of therapy) compared to the baseline level (Visit 1 Day 0 = Screening)The Swanson, Nolan and Pelham Teacher and Parent Rating Scale (SNAP-IV) is a 90-question self-report inventory designed to measure attention deficit hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) symptoms in children and young adults. The SNAP-IV is based on a 0 to 3 rating scale: Not at all = 0, Just a little = 1, Often = 2, and Very often = 3. The questions measure different domains of ADHD and ODD. Subscale scores on the SNAP-IV are calculated by summing the scores on the subset and dividing by the number of items in the subset. The score for any subset is expressed as the Average Rating-Per-Item. 28 point scale: min value 0, max value 27, higher scores mean a worse outcome.
Outcome measures
| Measure |
Main (Mexidol) + Control (Placebo)
n=111 Participants
Participants received Mexidol 125 mg 1 tablet orally once a day and Mexidol Placebo matching Mexidol 125 mg 1 tablet orally once a day for 42 days.
|
Main (Mexidol)
n=111 Participants
Participants received Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
Control (Placebo)
n=111 Participants
Participants received Mexidol Placebo matching Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
|---|---|---|---|
|
Average Change in the the Swanson, Nolan and Pelham Teacher and Parent Rating Scale (SNAP-IV), Subscale "Inattention"
SNAP-IV, Subscale "Inattention" at Visit 5
|
14.04 score on a scale
Standard Deviation 3.79
|
12.84 score on a scale
Standard Deviation 4.50
|
15.95 score on a scale
Standard Deviation 3.85
|
|
Average Change in the the Swanson, Nolan and Pelham Teacher and Parent Rating Scale (SNAP-IV), Subscale "Inattention"
Difference at Visit 5 compared to Visit 1
|
-3.80 score on a scale
Standard Deviation 3.62
|
-4.54 score on a scale
Standard Deviation 3.87
|
-2.05 score on a scale
Standard Deviation 3.55
|
SECONDARY outcome
Timeframe: Visit 5 (after 6 weeks of therapy) compared to the baseline level (Visit 1 Day 0 = Screening)The Swanson, Nolan and Pelham Teacher and Parent Rating Scale (SNAP-IV) is a 90-question self-report inventory designed to measure attention deficit hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) symptoms in children and young adults. The SNAP-IV is based on a 0 to 3 rating scale: Not at all = 0, Just a little = 1, Often = 2, and Very often = 3. The questions measure different domains of ADHD and ODD. Subscale scores on the SNAP-IV are calculated by summing the scores on the subset and dividing by the number of items in the subset. The score for any subset is expressed as the Average Rating-Per-Item. 28 point scale: min value 0, max value 27, higher scores mean a worse outcome.
Outcome measures
| Measure |
Main (Mexidol) + Control (Placebo)
n=111 Participants
Participants received Mexidol 125 mg 1 tablet orally once a day and Mexidol Placebo matching Mexidol 125 mg 1 tablet orally once a day for 42 days.
|
Main (Mexidol)
n=111 Participants
Participants received Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
Control (Placebo)
n=111 Participants
Participants received Mexidol Placebo matching Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
|---|---|---|---|
|
Average Change in the Swanson, Nolan and Pelham Teacher and Parent Rating Scale (SNAP-IV), Subscale "Hyperactivity/Impulsivity"
SNAP-IV, Subscale "Hyperactivity/Impulsivity" at Visit 5
|
11.38 score on a scale
Standard Deviation 5.06
|
10.20 score on a scale
Standard Deviation 4.58
|
13.15 score on a scale
Standard Deviation 4.76
|
|
Average Change in the Swanson, Nolan and Pelham Teacher and Parent Rating Scale (SNAP-IV), Subscale "Hyperactivity/Impulsivity"
Difference at Visit 5 compared to Visit 1
|
-3.50 score on a scale
Standard Deviation 3.36
|
-4.79 score on a scale
Standard Deviation 3.64
|
-1.87 score on a scale
Standard Deviation 3.28
|
SECONDARY outcome
Timeframe: Visit 5 (after 6 weeks of therapy) compared to the baseline level (Visit 1 Day 0 = Screening)The Swanson, Nolan and Pelham Teacher and Parent Rating Scale (SNAP-IV) is a 90-question self-report inventory designed to measure attention deficit hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) symptoms in children and young adults. The SNAP-IV is based on a 0 to 3 rating scale: Not at all = 0, Just a little = 1, Often = 2, and Very often = 3. The questions measure different domains of ADHD and ODD. Subscale scores on the SNAP-IV are calculated by summing the scores on the subset and dividing by the number of items in the subset. The score for any subset is expressed as the Average Rating-Per-Item. 25 point scale: min value 0, max value 24, higher scores mean a worse outcome.
Outcome measures
| Measure |
Main (Mexidol) + Control (Placebo)
n=111 Participants
Participants received Mexidol 125 mg 1 tablet orally once a day and Mexidol Placebo matching Mexidol 125 mg 1 tablet orally once a day for 42 days.
|
Main (Mexidol)
n=111 Participants
Participants received Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
Control (Placebo)
n=111 Participants
Participants received Mexidol Placebo matching Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
|---|---|---|---|
|
Average Change in the Swanson, Nolan and Pelham Teacher and Parent Rating Scale (SNAP-IV), Subscale "Oppositional Defiant Disorder"
SNAP-IV, Subscale "Oppositional Defiant Disorder" at Visit 5
|
4.06 score on a scale
Standard Deviation 4.91
|
3.69 score on a scale
Standard Deviation 4.88
|
4.43 score on a scale
Standard Deviation 4.48
|
|
Average Change in the Swanson, Nolan and Pelham Teacher and Parent Rating Scale (SNAP-IV), Subscale "Oppositional Defiant Disorder"
Difference at Visit 5 compared to Visit 1
|
-1.10 score on a scale
Standard Deviation 2.50
|
-0.95 score on a scale
Standard Deviation 2.57
|
-0.81 score on a scale
Standard Deviation 2.78
|
SECONDARY outcome
Timeframe: Visit 5 (after 6 weeks of therapy) compared to the baseline level (Visit 1 Day 0 = Screening)The Swanson, Nolan and Pelham Teacher and Parent Rating Scale (SNAP-IV) is a 90-question self-report inventory designed to measure attention deficit hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) symptoms in children and young adults. The SNAP-IV is based on a 0 to 3 rating scale: Not at all = 0, Just a little = 1, Often = 2, and Very often = 3. The questions measure different domains of ADHD and ODD. Subscale scores on the SNAP-IV are calculated by summing the scores on the subset and dividing by the number of items in the subset. The score for any subset is expressed as the Average Rating-Per-Item. 31 point scale: min value 0, max value 30, higher scores mean a worse outcome.
Outcome measures
| Measure |
Main (Mexidol) + Control (Placebo)
n=111 Participants
Participants received Mexidol 125 mg 1 tablet orally once a day and Mexidol Placebo matching Mexidol 125 mg 1 tablet orally once a day for 42 days.
|
Main (Mexidol)
n=111 Participants
Participants received Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
Control (Placebo)
n=111 Participants
Participants received Mexidol Placebo matching Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
|---|---|---|---|
|
Average Change in the Swanson, Nolan and Pelham Teacher and Parent Rating Scale (SNAP-IV), Subscale "Connors Index"
SNAP-IV), Subscale "Connors Index" at Visit 5
|
8.71 score on a scale
Standard Deviation 4.83
|
8.21 score on a scale
Standard Deviation 5.39
|
10.33 score on a scale
Standard Deviation 4.57
|
|
Average Change in the Swanson, Nolan and Pelham Teacher and Parent Rating Scale (SNAP-IV), Subscale "Connors Index"
Difference at Visit 5 compared to Visit 1
|
-3.32 score on a scale
Standard Deviation 2.99
|
-3.18 score on a scale
Standard Deviation 3.17
|
-2.00 score on a scale
Standard Deviation 3.37
|
SECONDARY outcome
Timeframe: Visit 5 (after 6 weeks of therapy) compared to the baseline level (Visit 2 Day 1 = Randomization Visit)The Spence Children's Anxiety Scale - Parent Version (SCAS-Parent) is a 39-item parent report measure designed to assess anxiety symptoms in children. Built upon contemporary diagnostic frameworks, the SCAS-Parent evaluates six distinct domains of anxiety that align with clinical diagnostic categories. Each question on the test addresses the frequency of certain anxiety symptoms, measured on a 0-3 scale from "never", "sometimes", "often", to "always". SCAS-Parent scores consist of a total raw score (range from 0 to 114) and six sub-scale scores, with higher scores indicating greater severity of anxiety symptoms. 124 point scale: min value 0, max value 123, higher scores mean a worse outcome.
Outcome measures
| Measure |
Main (Mexidol) + Control (Placebo)
n=111 Participants
Participants received Mexidol 125 mg 1 tablet orally once a day and Mexidol Placebo matching Mexidol 125 mg 1 tablet orally once a day for 42 days.
|
Main (Mexidol)
n=111 Participants
Participants received Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
Control (Placebo)
n=111 Participants
Participants received Mexidol Placebo matching Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
|---|---|---|---|
|
Average Change in the Spence Children's Anxiety Scale - Parent Version (SCAS-Parent) Score
SCAS-Parent at Visit 5
|
10.23 score on a scale
Standard Deviation 13.66
|
10.41 score on a scale
Standard Deviation 15.33
|
10.22 score on a scale
Standard Deviation 10.64
|
|
Average Change in the Spence Children's Anxiety Scale - Parent Version (SCAS-Parent) Score
Difference at Visit 5 compared to Visit 2
|
-2.90 score on a scale
Standard Deviation 5.45
|
-2.86 score on a scale
Standard Deviation 6.27
|
-3.05 score on a scale
Standard Deviation 6.76
|
SECONDARY outcome
Timeframe: Visit 5 (after 6 weeks of therapy) compared to the baseline level (Visit 2 Day 1 = Randomization Visit)The Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) is an 18-question inventory used to aid in the diagnosis of attention deficit hyperactivity disorder (ADHD) in children. Each question measures the frequency of the behavior on a 0-3 scale from "rarely or never", "sometimes", "often", to "very often". The questionnaire is intended to be filled out by parents and teachers. Higher scores indicate greater severity of ADHD symptoms. 55 point scale: min value 0, max value 54, higher scores mean a worse outcome.
Outcome measures
| Measure |
Main (Mexidol) + Control (Placebo)
n=111 Participants
Participants received Mexidol 125 mg 1 tablet orally once a day and Mexidol Placebo matching Mexidol 125 mg 1 tablet orally once a day for 42 days.
|
Main (Mexidol)
n=111 Participants
Participants received Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
Control (Placebo)
n=111 Participants
Participants received Mexidol Placebo matching Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
|---|---|---|---|
|
Average Change in the Attention Deficit Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Score
Difference at Visit 5 compared to Visit 2
|
-7.32 score on a scale
Standard Deviation 6.15
|
-9.54 score on a scale
Standard Deviation 6.88
|
-3.92 score on a scale
Standard Deviation 6.16
|
|
Average Change in the Attention Deficit Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Score
ADHD-RS-IV at Visit 5
|
25.23 score on a scale
Standard Deviation 8.01
|
23.14 score on a scale
Standard Deviation 8.26
|
28.85 score on a scale
Standard Deviation 7.68
|
SECONDARY outcome
Timeframe: Visit 5 (after 6 weeks of therapy) compared to the baseline level (Visit 2 Day 1 = Randomization Visit)The Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S) is a clinician-rated scale used to assess the severity of Attention Deficit Hyperactivity Disorder (ADHD) symptoms. This tool is part of the Clinical Global Impressions (CGI) scales. It typically consists of a single item that rates the severity of ADHD on a 7-point scale, ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). 7 point scale: min value 1, max value 7, higher scores mean a worse outcome.
Outcome measures
| Measure |
Main (Mexidol) + Control (Placebo)
n=111 Participants
Participants received Mexidol 125 mg 1 tablet orally once a day and Mexidol Placebo matching Mexidol 125 mg 1 tablet orally once a day for 42 days.
|
Main (Mexidol)
n=111 Participants
Participants received Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
Control (Placebo)
n=111 Participants
Participants received Mexidol Placebo matching Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
|---|---|---|---|
|
Assessment Using the Clinical Global Impressions for Attention Deficit Hyperactivity Disorder Severity (CGI-ADHD-S) Scale
Level 4 (moderately ill)
|
77 Participants
|
44 Participants
|
86 Participants
|
|
Assessment Using the Clinical Global Impressions for Attention Deficit Hyperactivity Disorder Severity (CGI-ADHD-S) Scale
Level 5 (markedly ill)
|
0 Participants
|
1 Participants
|
0 Participants
|
|
Assessment Using the Clinical Global Impressions for Attention Deficit Hyperactivity Disorder Severity (CGI-ADHD-S) Scale
Level 2 (borderline mentally ill)
|
8 Participants
|
8 Participants
|
2 Participants
|
|
Assessment Using the Clinical Global Impressions for Attention Deficit Hyperactivity Disorder Severity (CGI-ADHD-S) Scale
Level 3 (mildly ill)
|
26 Participants
|
58 Participants
|
23 Participants
|
SECONDARY outcome
Timeframe: Visit 5 (after 6 weeks of therapy) compared to the baseline level (before treatment)The Clinical Global Impressions (CGI) Scale is a standardized assessment tool used to rate the severity of illness, change over time, and efficacy of medication. It consists of 3 subscales. The subscale Clinical Global Impression-Improvement (CGI-I) is a 7-point scale that assesses how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention, and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. 7 point scale: min value 1, max value 7, higher scores mean a worse outcome.
Outcome measures
| Measure |
Main (Mexidol) + Control (Placebo)
n=111 Participants
Participants received Mexidol 125 mg 1 tablet orally once a day and Mexidol Placebo matching Mexidol 125 mg 1 tablet orally once a day for 42 days.
|
Main (Mexidol)
n=111 Participants
Participants received Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
Control (Placebo)
n=111 Participants
Participants received Mexidol Placebo matching Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
|---|---|---|---|
|
Assessment Using the Clinical Global Impressions Scale for Improvement (CGI-I)
7, very much worse
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Assessment Using the Clinical Global Impressions Scale for Improvement (CGI-I)
5, minimally worse
|
0 Participants
|
1 Participants
|
3 Participants
|
|
Assessment Using the Clinical Global Impressions Scale for Improvement (CGI-I)
6, much worse
|
0 Participants
|
1 Participants
|
0 Participants
|
|
Assessment Using the Clinical Global Impressions Scale for Improvement (CGI-I)
1, very much improved
|
3 Participants
|
13 Participants
|
2 Participants
|
|
Assessment Using the Clinical Global Impressions Scale for Improvement (CGI-I)
2, much improved
|
20 Participants
|
45 Participants
|
10 Participants
|
|
Assessment Using the Clinical Global Impressions Scale for Improvement (CGI-I)
3, minimally improved
|
61 Participants
|
37 Participants
|
38 Participants
|
|
Assessment Using the Clinical Global Impressions Scale for Improvement (CGI-I)
4, no change
|
27 Participants
|
14 Participants
|
58 Participants
|
SECONDARY outcome
Timeframe: Visit 5 (after 6 weeks of therapy) compared to the baseline level (Visit 2 Day1 = Randomization Visit)Population: The scores on this questionnaire were evaluated only for patients who were found tohave a headache. Thus, the data for comparing the results at the end of the therapy withthe results at the beginning of the therapy were available for 18 patients.
The Pediatric Migraine Disability Assessment questionnaire (PedMIDAS) is used to assess the impact of headaches on school performance (three questions), activities at home (one question on homework or chores), and social and/or sports functions (two questions). The PedMIDAS is scored by summing the answers across the six questions. The frequency and severity are not scored but can be used for clinical reference. PedMIDAS score range from 0 to 10 indicates little to none disability grade, score range from 11 to 30 indicates mild disability grade, score range from 31 to 50 indicates moderate disability grade and score range greater than 50 indicates severe disability grade. Min value 0, max value 240, higher scores mean a worse outcome.
Outcome measures
| Measure |
Main (Mexidol) + Control (Placebo)
n=8 Participants
Participants received Mexidol 125 mg 1 tablet orally once a day and Mexidol Placebo matching Mexidol 125 mg 1 tablet orally once a day for 42 days.
|
Main (Mexidol)
n=3 Participants
Participants received Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
Control (Placebo)
n=7 Participants
Participants received Mexidol Placebo matching Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
|---|---|---|---|
|
Assessment Using the Pediatric Migraine Disability Assessment Questionnaire (PedMIDAS), Days
Number of days with limited daily activities
|
4.25 days
Standard Deviation 10.97
|
0.22 days
Standard Deviation 0.38
|
2.38 days
Standard Deviation 2.03
|
|
Assessment Using the Pediatric Migraine Disability Assessment Questionnaire (PedMIDAS), Days
No of days with limited activity: Visit 5 compared to Visit 2
|
-6.71 days
Standard Deviation 11.77
|
-0.33 days
Standard Deviation 0.33
|
0.76 days
Standard Deviation 1.46
|
|
Assessment Using the Pediatric Migraine Disability Assessment Questionnaire (PedMIDAS), Days
Number of days with a headache
|
9.58 days
Standard Deviation 10.73
|
5.11 days
Standard Deviation 2.52
|
4.95 days
Standard Deviation 2.52
|
|
Assessment Using the Pediatric Migraine Disability Assessment Questionnaire (PedMIDAS), Days
No of days with headache: Visit 5 compared to Visit 2
|
0.54 days
Standard Deviation 8.45
|
1.89 days
Standard Deviation 4.72
|
0.10 days
Standard Deviation 3.72
|
SECONDARY outcome
Timeframe: Visit 5 (after 6 weeks of therapy) compared to the baseline level (Visit 2 Day1 = Randomization Visit)The Pediatric Migraine Disability Assessment questionnaire (PedMIDAS) is used to assess the impact of headaches on school performance (three questions), activities at home (one question on homework or chores), and social and/or sports functions (two questions). The PedMIDAS is scored by summing the answers across the six questions. The frequency and severity are not scored but can be used for clinical reference. PedMIDAS score range from 0 to 10 indicates little to none disability grade, score range from 11 to 30 indicates mild disability grade, score range from 31 to 50 indicates moderate disability grade and score range greater than 50 indicates severe disability grade. Min value 0, max value 240, higher scores mean a worse outcome.
Outcome measures
| Measure |
Main (Mexidol) + Control (Placebo)
n=8 Participants
Participants received Mexidol 125 mg 1 tablet orally once a day and Mexidol Placebo matching Mexidol 125 mg 1 tablet orally once a day for 42 days.
|
Main (Mexidol)
n=3 Participants
Participants received Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
Control (Placebo)
n=7 Participants
Participants received Mexidol Placebo matching Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
|---|---|---|---|
|
Assessment Using the Pediatric Migraine Disability Assessment Questionnaire (PedMIDAS), Headache Severity
Moderate headache severity
|
3.88 score on a scale
Standard Deviation 2.10
|
3.00 score on a scale
Standard Deviation 1.00
|
3.71 score on a scale
Standard Deviation 1.25
|
|
Assessment Using the Pediatric Migraine Disability Assessment Questionnaire (PedMIDAS), Headache Severity
Moderate headache: Visit 5 compared to Visit 2
|
-0.38 score on a scale
Standard Deviation 1.19
|
0.00 score on a scale
Standard Deviation 0.00
|
-0.14 score on a scale
Standard Deviation 0.90
|
|
Assessment Using the Pediatric Migraine Disability Assessment Questionnaire (PedMIDAS), Headache Severity
Maximal headache severity
|
6.13 score on a scale
Standard Deviation 3.00
|
5.33 score on a scale
Standard Deviation 2.31
|
5.57 score on a scale
Standard Deviation 1.51
|
|
Assessment Using the Pediatric Migraine Disability Assessment Questionnaire (PedMIDAS), Headache Severity
Max headache: Visit 5 compared to Visit 2
|
0.38 score on a scale
Standard Deviation 1.85
|
1.33 score on a scale
Standard Deviation 2.31
|
-0.57 score on a scale
Standard Deviation 1.72
|
Adverse Events
Main (Mexidol) + Control (Placebo)
Main (Mexidol)
Control (Placebo)
Serious adverse events
| Measure |
Main (Mexidol) + Control (Placebo)
n=111 participants at risk
Participants received Mexidol 125 mg 1 tablet orally once a day and Mexidol Placebo matching Mexidol 125 mg 1 tablet orally once a day for 42 days.
|
Main (Mexidol)
n=111 participants at risk
Participants received Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
Control (Placebo)
n=111 participants at risk
Participants received Mexidol Placebo matching Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
|---|---|---|---|
|
Infections and infestations
Respiratory tract infection
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Infections and infestations
Furuncle
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
Other adverse events
| Measure |
Main (Mexidol) + Control (Placebo)
n=111 participants at risk
Participants received Mexidol 125 mg 1 tablet orally once a day and Mexidol Placebo matching Mexidol 125 mg 1 tablet orally once a day for 42 days.
|
Main (Mexidol)
n=111 participants at risk
Participants received Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
Control (Placebo)
n=111 participants at risk
Participants received Mexidol Placebo matching Mexidol 125 mg 1 tablet orally twice a day for 42 days.
|
|---|---|---|---|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.90%
1/111 • Number of events 2 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
1.8%
2/111 • Number of events 2 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Gastrointestinal disorders
Irritable bowel syndrome
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Gastrointestinal disorders
Nausea
|
1.8%
2/111 • Number of events 2 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
1.8%
2/111 • Number of events 2 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
1.8%
2/111 • Number of events 2 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Infections and infestations
Respiratory tract infection
|
1.8%
2/111 • Number of events 2 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
1.8%
2/111 • Number of events 2 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
3.6%
4/111 • Number of events 4 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Infections and infestations
Nasopharyngitis
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Infections and infestations
Herpes zoster
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Infections and infestations
Otosalpingitis
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Infections and infestations
Rhinitis
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
3.6%
4/111 • Number of events 4 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
2.7%
3/111 • Number of events 3 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Infections and infestations
Sinusitis
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Infections and infestations
Furuncle
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
1.8%
2/111 • Number of events 2 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Immune system disorders
Oral allergy syndrome
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Immune system disorders
Seasonal allergy
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Nervous system disorders
Headache
|
1.8%
2/111 • Number of events 2 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
2.7%
3/111 • Number of events 4 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
1.8%
2/111 • Number of events 2 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Nervous system disorders
Disturbance in attention
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Eye disorders
Meibomianitis
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Renal and urinary disorders
Urine abnormality
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Renal and urinary disorders
Leukocyturia
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Psychiatric disorders
Agitation
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Psychiatric disorders
Affect lability
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Psychiatric disorders
Listless
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Psychiatric disorders
Inappropriate affect
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
|
Injury, poisoning and procedural complications
Animal bite
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.00%
0/111 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
0.90%
1/111 • Number of events 1 • From Day 1 (Visit 2) to Day 50+3 (Visit 6) or Early Termination Visit
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: GT60